Ken Griffin Lineage Cell Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.12 $480 - $672	600 Added 150.0%	1,000 $0
Q2 2024 Aug 14, 2024	BUY	$0.89 - $1.47 $356 - $588	400 New	400 $0
Q4 2023 Feb 14, 2024	BUY	$0.91 - $1.35 $819 - $1,215	900 New	900 $0
Q1 2023 May 15, 2023	SELL	$1.2 - $1.53 $1,200 - $1,530	-1,000 Reduced 66.67%	500 $0
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $1,530 - $2,250	1,500 New	1,500 $1,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $96.8M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.